Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

Inclusion criteria

• ✓. Male or female patients aged 3-65 years old;
• ✓. Systemic lupus erythematosus that meets the 2019 American College of Rheumatology (ACR)/European Union of Rheumatology Associations (EULAR) classification criteria (see Annex 5);
• ✓. The result of the anti nuclear antibody (ANA) test is clearly positive, that is, the ANA titer is ≥ 1:80 (equivalent test result based on Hep-2 immunofluorescence detection method or enzyme immunoassay method), and/or at the screening visit, the anti dsDNA serum antibody test is positive (≥ 30 IU/mL based on ELISA detection method) according to the test results of the research center laboratory.
• ✓. B cell CD19+expression and discontinuation of immunosuppressive agents for more than 1 week;
• ✓. No severe allergic constitution;
• ✓. Physical condition score (ECOG) 0-2 points;
• ✓. Expected survival period ≥ 90 days;
• ✓. The subjects and/or their guardians are able to understand and willing to sign a written informed consent form; 2. Systemic sclerosis (SSc):